Chapter 44. Mantle Cell Lymphoma

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8,
  5. Richard Lottenberg MD, FACP Professor9
  1. C. Tom Kouroukis MD MSc FRCPC

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch44

Book Title

Evidence-Based Hematology

Evidence-Based Hematology

Additional Information

How to Cite

Kouroukis, C. T. (2009) Mantle Cell Lymphoma, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch44

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. Hematology-Oncology, Juravinski Cancer Centre, Department of Oncology, McMaster University, Hamilton, Ontario, Canada

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857

SEARCH

CHAPTER TOOLS

Get PDF (280K)

Keywords:

  • mantle cell lymphoma (MCL);
  • literature-search strategy and results;
  • role of anthracycline or anthracenedione-based chemotherapy in adults;
  • anthracycline-containing therapy - CHOP;
  • role of rituximab (single agent, in combination with chemotherapy) in adult MCL;
  • rituximab as component of multiagent therapy;
  • high dose chemotherapy and stem cell transplantation in relapsed MCL

Summary

This chapter contains sections titled:

  • Introduction

  • Questions

  • Literature-search strategy and results

  • What is the role of anthracycline or anthracenedione-based chemotherapy in adults with newly diagnosed or relapsed MCL?

  • What is the role of rituximab (as a single agent, in combination with chemotherapy) in adults with newly diagnosed or relapsed MCL?

  • What is the role of high dose chemotherapy and stem cell transplantation in patients with newly diagnosed or relapsed MCL?

  • References

  • Appendix

Get PDF (280K)